Cora N. Sternberg, MD, on Renal and Bladder Cancers: Focus on Immunotherapy
ESMO 2018 CongressCora N. Sternberg, MD, of San Camillo-Forlanini Hospital and the Israel Englander Institute of Precision Medicine at Weill Cornell, discusses results from the phase III CheckMate-025 study on nivolumab vs everolimus for mRCC; the CheckMate-214 study on nivolumab, ipilimumab, and sunitinib for treatment-naive advanced or metastatic clear-cell RCC; and immunotherapy for urothelial cancer for both first- line cisplatin-ineligible and second-line therapy after cisplatin chemotherapy.
Related Videos
Matthew J. Ellis, MB, BChir, PhD, on Breast Cancer: Neoadjuvant Endocrine Therapy
Matthew J. Ellis, MB, BChir, PhD, of the Baylor College of Medicine, discusses data on endocrine therapy alone or in combination with targeted treatments for postmenopausal women w...
Matti S. Aapro, MD, on Immunotherapy in Older Patients
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining...
Caroline Robert, MD, PhD, on Advanced Melanoma: Research Highlights
Caroline Robert, MD, PhD, of Gustave Roussy Cancer Centre, discusses two high-impact studies in stage III melanoma treatment: an update of the COMBI-AD trial examining dabrafenib a...
Tony Mok, MD, on NSCLC: Targeted Treatment Update
Tony Mok, MD, of the Chinese University of Hong Kong, discusses two important studies in non–small cell lung cancer: FLAURA, which looked at the first-line activity of osimertinib ...
Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder ca...
